Agreement - May 26, 2021
Zelluna Immunotherapy enters license agreement
The company has announced two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the treatment of various solid cancers. Under the agreements Zelluna will have exclusive rights from MD Anderson to use characterized TCRs targeting MAGE-A4 and VGLL1 for […]
Collaboration - June 26, 2020
Zelluna collaborates with Lion TCR
Zelluna Immunotherapy has announced a research collaboration agreement with Lion TCR (Singapore). The collaboration will focus on the development of TCR-NK products for the treatment of virally induced cancers. “This collaboration represents a key milestone for Zelluna and marks an important aspect of our strategy which is to expand our pipeline through in-licensing and partnering,” […]
Financing - June 16, 2020
Zelluna Immunotherapy raises 7.5 million EUR
Zelluna Immunotherapy has announced the completion of a fundraise to fully focus on the development of its TCR guided Natural Killer (NK) cell therapy platform (TCR-NK) for the treatment of cancers. A total of approximately EUR 7.5 million has been raised in equity financing and public grants. Zelluna’s strategy is to concentrate on the development […]
Collaboration - March 12, 2020
Zelluna and Karolinska Institutet collaborate
Zelluna Immunotherapy and Karolinska Institutet have announced a collaboration to develop next generation TCR-NK products for the treatment of patients with solid cancers. In addition, Zelluna is entered as a collaborative partner in the new Competence Center for Next-Generation NK Cell-based Cancer Immunotherapy (“NextGenNK”) being established at the KI. Next generation TCR guided NK cells […]
In a new job - December 19, 2019
Namir Hassan is the new CEO of Zelluna Immunotherapy
Zelluna Immunotherapy has announced the appointment of Namir Hassan as its chief executive officer (CEO). “At this stage of Zelluna’s evolution, we are delighted to appoint Namir Hassan as CEO. Namir has made an invaluable contribution to Zelluna since he joined the company in 2018 as chief scientific officer (CSO). He has a strong scientific […]
Agreement - November 19, 2019
Zelluna Immunotherapy and Glycostem Therapeutics announce collaboration agreement
Zelluna Immunotherapy and Glycostem Therapeutics have announce that they have entered into a development, license and supply agreement. This collaboration will focus on the development and manufacture of allogeneic TCR guided NK-cell therapies (TCR-NK’s) for the treatment of patients with cancer. “This partnership between Zelluna and Glycostem represents a critical milestone in Zelluna’s aim to […]
